Canine pyoderma and methicillin-resistant staphylococcal infection

Doses on this pageEvery dose below is quoted from the cited source. Verify against the current label/formulary and the patient's full clinical picture.

What pyoderma is and which dogs get it

Pyoderma usually refers to bacterial infection of the skin. The Merck Veterinary Manual notes the term literally means "pus in the skin." It also states that superficial bacterial pyoderma is the most frequent reason for antimicrobial use in small animal practice [2]. The main pathogen is Staphylococcus pseudintermedius, a commensal that a 2024 review reports colonizing 77-90% of healthy dogs [4].

The ISCAID panel describes pyoderma as always secondary to an underlying primary cause [1]. The guidelines name trauma, ectoparasites and atopic skin disease as the most common triggers, with cornification disorders, endocrinopathies and neoplasia also to be considered [1]. Merck adds anatomical predispositions such as skin folds, immune-mediated disease and demodicosis [2].

A Canadian Veterinary Journal review by Curran and Ward suggests age can steer the workup. Ectoparasites and allergy rank higher in dogs under 3 years, and neoplasia or endocrinopathy rank higher in older dogs [3].

Classification by depth

ISCAID classifies pyoderma by histological depth, and treatment recommendations follow that classification [1].

Table content is from the ISCAID synopsis [1].

Curran and Ward caution that no single lesion type is pathognomonic for a given depth [3]. They also point out that haemorrhagic discharge can help separate deep pyoderma from shallower forms, because the dermis contains blood vessels [3]. The guidelines describe deep pyoderma as potentially serious, with a risk of spread through the blood and progression to septicaemia [1].

Diagnosis and testing pitfalls

ISCAID recommends a three-step approach [1]:

1. Examine the whole skin to identify lesion type and depth.
2. Confirm bacteria by cytology.
3. Consider the primary cause from the first occurrence.

The panel treats the following cytology findings as supportive of pyoderma [1]:

• intracellular bacteria
• extracellular bacteria with nuclear streaking
• in bacterial overgrowth, large numbers of bacteria without inflammatory cells

Merck also lists ruling out demodicosis and dermatophytosis, noting that negative deep skin scrapings exclude follicular demodicosis in most cases [2].

ISCAID recommends bacterial culture and antimicrobial susceptibility testing (BC/AST) whenever systemic therapy is planned. Testing is "always strongly recommended" when resistance risk is raised [1]. Curran and Ward list these risk factors [3]:

• recurrent pyoderma
• more than one systemic course in the previous 6 months
• patient or household history of MRS
• poor response after 5 to 7 days of appropriate systemic therapy
• new lesions during treatment
• high local MRSP prevalence
• rods or mixed populations on cytology

They add that methicillin-resistant and methicillin-susceptible infections cannot be told apart clinically [3].

Several pitfalls appear in the sources:

• Culture results need cytology alongside them. Curran and Ward describe a prospective US study in which cultures from superficial pyoderma lesions were sent to 3 laboratories. Agreement on staphylococci was good, but results for other bacterial species varied more widely, which could change drug selection [3]. The review does not state how many dogs were sampled.
• Breakpoints. ISCAID advises using laboratories that apply veterinary breakpoints, which the synopsis says are currently published only by CLSI [1].
• Coagulase-negative staphylococci. Methicillin resistance in coagulase-negative staphylococci from skin may be of doubtful clinical relevance, per the guidelines [1].
• Inducible clindamycin resistance. Merck warns that this can occur. Isolates reported as erythromycin resistant but clindamycin susceptible should have a D test before clindamycin is chosen [2].
• Sterile mimics. Curran and Ward note that sterile conditions such as pemphigus foliaceus can produce similar lesions, which is one reason cytology is required [3].

Topical therapy

The ISCAID panel names topical therapy alone as the treatment of choice for all surface and superficial pyoderma, and as an adjunct whenever systemic drugs are used [1]. The guidelines prioritise antiseptics over topical antibiotics such as fusidic acid and mupirocin. They identify 2-4% chlorhexidine as the agent with the greatest support for efficacy [1].

According to the panel, the following also had good-quality evidence [1]:

• benzoyl peroxide
• olanexidine
• a chlorhexidine/miconazole combination
• a dilute sodium hypochlorite/salicylic acid product

ISCAID notes that household bleach must be diluted to below 0.05% to be considered safe for dogs and owners [1].

Curran and Ward cite several studies [3]:

• 2015 study: twice-weekly 4% chlorhexidine shampoo plus a daily spray performed as well as systemic amoxicillin-clavulanic acid for superficial pyoderma over 4 weeks.
• 2025 US study: no significant difference between twice-daily 3% chlorhexidine and 70% ethyl alcohol. The reviewers say this needs further investigation.
• Contact time: a shampoo contact time as short as 3 minutes was suggested as noninferior in a prospective study of only 9 dogs.

Merck describes medicated bathing 2 to 3 times weekly with 10 to 15 minutes of contact [2].

For superficial pyoderma, ISCAID advises veterinary reassessment after 2 to 3 weeks of topical therapy. It reports that topical therapy alone was effective in 12 of 13 published clinical trials it reviewed [1]. For surface pyoderma, the panel says topical or short-course systemic glucocorticoids may help where an inflammatory or pruritic cause is involved [1].

Systemic therapy and drug tiers

ISCAID sorts systemic drugs into four groups [1]:

• First-choice: amoxicillin-clavulanate, cefalexin, cefadroxil, clindamycin and lincomycin, with expected efficacy against most methicillin-susceptible staphylococci.
• Second-choice: used only when BC/AST shows susceptibility and first-choice drugs are unsuitable. The list includes cefovecin, cefpodoxime, fluoroquinolones, doxycycline, minocycline, trimethoprim-sulfadiazine or -sulfamethoxazole, and ormetoprim-sulfadimethoxine.
• Reserved: rifampicin, amikacin, gentamicin and chloramphenicol, for multidrug-resistant staphylococci after confirmed susceptibility.
• Strongly discouraged: linezolid and vancomycin. The guidelines say their use in all animals has been banned in the EU since 2023.

The guidelines give these first-choice dosages [1]:

• amoxicillin-clavulanate 12.5 mg/kg p.o. q12h
• cefalexin or cefadroxil 22-25 mg/kg p.o. q12h
• clindamycin 11 mg/kg p.o. q12h

Merck lists clindamycin at 11 mg/kg PO every 24 hours, so the two sources differ on frequency [2]. ISCAID notes its dosages may deviate from earlier recommendations and datasheets [1].

On duration, the guidelines describe an initial 2-week course for superficial and 3-week course for deep pyoderma, with re-examination before the course ends [1]. Deep cases still improving are rechecked every 2 weeks. The panel says "it should be very rare" for more than 6 weeks of appropriate therapy to be needed [1].

For deep pyoderma, ISCAID states drug choice "should always be based on BC/AST results." Empirical treatment guided by cytology may start immediately if deterioration or septicaemia is a risk [1]. Merck advises reconsidering the diagnosis if there is no response after 3 to 4 days [2].

Methicillin-resistant staphylococci

ISCAID states that its depth-based recommendations apply equally to pyoderma caused by MRSP, MRSA and methicillin-resistant S. coagulans [1]. Topical therapy alone remains the panel's treatment of choice for surface and superficial MRS pyoderma [1]. If systemic therapy is needed, the guidelines direct prescribers to non-beta-lactam first- or second-choice drugs reported as susceptible [1].

A 2024 narrative review in Veterinary Research Communications covers resistance and treatment options in MRSP [4]:

• Resistance pattern: resistance can extend across tetracyclines, macrolides, lincosamides, aminoglycosides, trimethoprim-sulfamethoxazole and fluoroquinolones.
• Driver: beta-lactam use, about 70% of veterinary antimicrobial consumption in the surveys the authors cite, appears to be the main driver of MRSP selection.
• Lineages: clonal lineages are shifting by region, with ST258 appearing more susceptible to veterinary-licensed drugs than ST71.
• Low-level MRSP: the review cites a retrospective clinical study by Pirolo et al. in which dogs infected with low-level MRSP were treated successfully with beta-lactams. The review's authors argue that beta-lactam breakpoints should be revised. This sits against current CLSI guidance, which the review says reports oxacillin-resistant isolates as resistant to all beta-lactams.
• Alternatives: iron chelators, antimicrobial peptides, nanoparticles and bacteriophages are described largely on the basis of in vitro work.

Prognosis, recurrence and client communication

The ISCAID panel considers the prognosis for MRS pyoderma good, noting that infection control and potential zoonotic transmission require attention [1]. The 2024 review reports human colonization and infection with S. pseudintermedius, mainly linked to close contact with pet dogs [4].

For dogs needing systemic therapy more than once a year, the guidelines say the search for a primary cause must be intensified, with a diagnostic review at least every 6 to 12 months [1]. In allergic dogs, the panel prioritises allergy management over repeated antimicrobials, and proactive antiseptic therapy may be maintained indefinitely [1]. Curran and Ward describe prophylactic antiseptic use 2 or 3 times weekly [3].

The guidelines suggest owners be told that the cost of resistance may exceed the cost of BC/AST if empirical drugs fail, and that practices price testing reasonably [1]. Before reserved drugs are used, ISCAID advises owners be made aware of the risks and the need for compliance [1].

Before using any dose aboveVerify against the current label/formulary and the patient's full clinical picture.